Last 12 months
Inside the activity.
0 purchase rows · 34 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC |
Wotton Paul KDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-021502 · form4.xml · derivative · entry 2 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC |
Wotton Paul KDirector
|
Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-021502 · form4.xml · nonDerivative · entry 1 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 27, 2022. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC |
Rubino Alan LDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-021497 · form4.xml · derivative · entry 2 Rubino Alan L · CIK 0001340228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC |
Rubino Alan LDirector
|
Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-021497 · form4.xml · nonDerivative · entry 1 Rubino Alan L · CIK 0001340228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 27, 2022. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 20:03 UTC |
Rubino Alan LDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001140361-23-020911 · form4.xml · derivative · entry 2 Rubino Alan L · CIK 0001340228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2023-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 3,000 shares, were originally granted on May 2, 2013, and became exerciseable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 20:03 UTC |
Rubino Alan LDirector
|
Exercise / conversionCommon Stock | 3,000 | $10.60 | $31,800.00 |
DisclosureSEC source: 0001140361-23-020911 · form4.xml · nonDerivative · entry 1 Rubino Alan L · CIK 0001340228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| March 31, 2023 Filed Feb 13, 2024 11:01 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantCommon Stock | 114 | $21.36 | $2,435.04 |
DisclosureSEC source: 0001140361-24-007195 · form5.xml · nonDerivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,811 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-23-008724 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2023-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 3,000 shares, were originally granted on May 2, 2013, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionCommon Stock | 3,000 | $10.60 | $31,800.00 |
DisclosureSEC source: 0001127602-23-008724 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · derivative · entry 9 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,613 Underlying: Common Stock · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 1,868 | $29.82 | $55,703.76 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · nonDerivative · entry 4 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,721 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 3,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · nonDerivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 752 | $29.82 | $22,424.64 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,412 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · derivative · entry 9 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024, and February 19, 2025. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
Tax withholdingCommon Stock | 832 | $29.82 | $24,810.24 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · nonDerivative · entry 4 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,176 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · nonDerivative · entry 3 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024, and February 19, 2025. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 9 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,875 Underlying: Common Stock · 8,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024, and February 19, 2025, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 8,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024, and February 19, 2025, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 4,143 | $29.82 | $123,544.26 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,808 F1 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 03:00 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 419 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006604 · form4.xml · derivative · entry 6 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Underlying: Common Stock · 419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 03:00 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 162 | $29.82 | $4,830.84 |
DisclosureSEC source: 0001127602-23-006604 · form4.xml · nonDerivative · entry 2 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 03:00 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 419 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006604 · form4.xml · nonDerivative · entry 1 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · derivative · entry 8 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,487 Underlying: Common Stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 1,332 | $29.82 | $39,720.24 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,764 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 2,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 1,108 | $29.82 | $33,040.56 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,414 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 2,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:55 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006583 · form4.xml · derivative · entry 6 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,264 Underlying: Common Stock · 2,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:55 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Tax withholdingCommon Stock | 1,065 | $29.82 | $31,758.30 |
DisclosureSEC source: 0001127602-23-006583 · form4.xml · nonDerivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,697 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:55 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionCommon Stock | 2,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006583 · form4.xml · nonDerivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · derivative · entry 8 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 2,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
Tax withholdingCommon Stock | 1,155 | $29.82 | $34,442.10 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · nonDerivative · entry 2 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,258 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
Exercise / conversionCommon Stock | 2,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · nonDerivative · entry 1 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 8 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,100 Underlying: Common Stock · 11,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 5,423 | $29.82 | $161,713.86 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,013 F1 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 03:00 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006604 · form4.xml · derivative · entry 5 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F6 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 03:00 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 6,187 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006604 · form4.xml · derivative · entry 4 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,187 Underlying: Common Stock · 6,187 shares Expires 2033-02-17 F4 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 03:00 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 2,813 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006604 · form4.xml · derivative · entry 3 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813 Underlying: Common Stock · 2,813 shares Expires 2033-02-17 F4 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
GrantRestricted Stock Unit · Derivative | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · derivative · entry 7 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 49,218 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · derivative · entry 6 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,218 Underlying: Common Stock · 49,218 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 02:02 UTC |
Halpin MichaelChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 3,282 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006590 · form4.xml · derivative · entry 5 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,282 Underlying: Common Stock · 3,282 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 28,125 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · derivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:57 UTC |
Hopper Jonathan MarkChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006586 · form4.xml · derivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:55 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006583 · form4.xml · derivative · entry 5 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:55 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,359 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006583 · form4.xml · derivative · entry 4 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,359 Underlying: Common Stock · 43,359 shares Expires 2033-02-17 F4 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.